Physician profile
Phillip Wayne Comalander
NPI 1376086553
$6,564.02
in general payments reported to CMS, 2019-2025
28 companies · $2,266 in 2025
The $2,266 reported for 2025 was more than what 95% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $712 · 2022: $1,008 · 2023: $952 · 2024: $1,625 · 2025: $2,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,759 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,759.43 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,242.72 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $556.67 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $538.55 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $466.31 | 2021-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $455.19 | 2021-2024 | Trulance, Xifaxan, Relistor |
| Janssen Biotech, INC. | $424.17 | 2021-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $366.93 | 2022-2025 | Epclusa |
| Lilly USA, LLC | $183.33 | 2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $175.33 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $166.91 | 2021-2023 | Dificid |
| Braintree Laboratories, INC. | $154.87 | 2022-2024 | Suflave |
| Aimmune Therapeutics, INC. | $139.25 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $137.01 | 2021-2023 | Linzess |
| Ardelyx, INC. | $81.44 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $70.08 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $60.06 | 2021 | |
| Pfizer INC. | $58.10 | 2024-2025 | |
| Genzyme Corporation | $57.78 | 2022 | |
| Redhill Biopharma INC. | $45.70 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $40.23 | 2021-2022 | |
| Novo Nordisk INC | $28.20 | 2025 | Wegovy |
| Alcresta Therapeutics, INC. | $20.71 | 2022 | |
| Daiichi Sankyo INC. | $19.17 | 2021 | |
| Celgene Corporation | $18.32 | 2022 | |
| Ferring Pharmaceuticals INC. | $15.12 | 2023 | Cimzia |
| Exact Sciences Corporation | $14.49 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $14.25 | 2023 | |
| Fresenius Kabi USA, LLC | $13.13 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Comalander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.